stockrowSerina Therapeutics, Inc.
Serina Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $130,000.00, up 132.1% from fiscal 2024.
- Revenue
- +2,500.0%
- EPS
- +16.7%
- Free cash flow
- −76.8%
Quarter to June 2026, against a year earlier
Follow SER
Alert me
Serina Therapeutics, Inc. (SER) EV/Sales
As of 6 November 2026, Serina Therapeutics, Inc. (SER) trades at a EV/Sales of 32.5×. Over the past ten years it has ranged from −2.4× (May 2026) to 1,870× (June 2023); the current reading is higher than 24% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 123× | (81.75%) |
| FY2024 | 673× | 7,021.21% |
| FY2023 | 9.5× | (99.17%) |
| FY2022 | 1,138× | 204.19% |
| FY2021 | 374× | 114.51% |
| FY2020 | 174× | 347.35% |
| FY2019 | 39.0× | (45.74%) |
| FY2018 | 71.9× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2025 | 332× | (50.69%) |
| Dec 2024 | 673× | 3,411.34% |
| Sep 2024 | 19.2× | (15.93%) |
| Jun 2024 | 22.8× | 147.64% |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BMEA Biomea Fusion, Inc. compare | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| ATNM Actinium Pharmaceuticals, Inc. compare | 0.2× |
| SGMOQ Sangamo Therapeutics, Inc. compare | 1.2× |
| HYPD Hyperion DeFi, Inc. compare | 24.6× |
| SER Serina Therapeutics, Inc. | 32.5× |
| GANX Gain Therapeutics, Inc. compare | 154× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)